Caption Management Adds $6M in Avalo Therapeutics, Inc. ($AVTX)
Key Points
- Caption Management changed its Avalo Therapeutics, Inc. ($AVTX) stake by 764.3% last quarter, boosting to 455,000 shares worth $6.72 million.
- Wall Street's consensus rating on $AVTX is Strong Buy and an average price target of $45.25.
- $AVTX last traded around $14.76.
Caption Management increased its position in Avalo Therapeutics, Inc. ($AVTX) by 764.3% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 455,000 shares of Avalo Therapeutics, Inc. after buying 402,359 shares during the quarter. Caption Management's holdings in Avalo Therapeutics, Inc. were worth $6.72 million as of its most recent filing.
Avalo Therapeutics, Inc. ($AVTX) Stock
Avalo Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.